ESTRO 2024 - Abstract Book

S1410

Clinical - Head & neck

ESTRO 2024

Figure 2: Scatter plot of log2 Baseline cfDNA vs GTVt, with linear best fit model and 95% confidence intervals.

Conclusion:

These data show a weak but statistically significant association between baseline HPV cfDNA titres, and disease volume in patients with non-metastatic p16 positive OPSCC. This preliminary finding is based upon a limited sample, and requires further analysis of remaining samples, and external validation. However, the fact that total disease volume (GTVt) shows the strongest association with baseline HPV cfDNA titres supports the notion that this is a true effect. These data suggest that HPV cfDNA can help to quantify disease burden in p16 positive HPV positive OPSCC, and may therefore be a useful biomarker in analysing response to therapy and as a monitoring tool in follow-up.

Keywords: cell free DNA, liquid biopsy

References:

(1) Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019 Jan 5;393(10166):51-60. (2) O’Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016 Apr;17(4):440-451.